Rifaximin intake leads to emergence of rifampin-resistant staphylococci

Journal of Infection

Volumn 62, Issue 1, 2011, Pages 34-38

  Valentin, Thomas ^a   Leitner, Eva ^a   Rohn, Angelika ^a   Zollner Schwetz, Ines ^a   Hoenigl, Martin ^a   Salzer, Helmut J F ^a   Krause, Robert ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Foreign body infections; Resistance; Rifampin; Rifaximin

Indexed keywords

RIFAMPICIN; RIFAXIMIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL TRIAL; DIARRHEA; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPSILOMETER TEST; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; SKIN FLORA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS LUGDUNENSIS; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; RIFAMYCINS; SKIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 78751637130     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.11.004     Document Type: Article

References (46)

1. Darouiche R.O. Treatment of infections associated with surgical implants. N Engl J Med 2004, 350:1422-1429.
2. Harris L.G., Richards R.G. Staphylococci and implant surfaces: a review. Injury 2006, 37(Suppl. 2):S3-S14.
3. Bonow R.O., Carabello B.A., Chatterjee K., de Leon A.C., Faxon D.P., Freed M.D., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American heart Association Task Force on Practice guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008, 52:e1-142.
4. Zimmerli W., Trampuz A., Ochsner P.E. Prosthetic-joint infections. N Engl J Med 2004, 351:1645-1654.
5. Daver N.G., Shelburne S.A., Atmar R.L., Giordano T.P., Stager C.E., Reitman C.A., et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007, 54:539-544.
6. Dombrowski J.C., Winston L.G. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J Infect 2008, 57:110-115.
7. Villain-Guillot P., Gualtieri M., Bastide L., Leonetti J.P. In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2007, 51:3117-3121.
8. Zimmerli W., Widmer A.F., Blatter M., Frei R., Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998, 279:1537-1541.
9. Drancourt M., Stein A., Argenson J.N., Roiron R., Groulier P., Raoult D. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997, 39:235-240.
10. Conen A., Walti L.N., Merlo A., Fluckiger U., Battegay M., Trampuz A. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008, 47:73-82.
11. Livermore D.M. Antibiotic resistance in staphylococci. Int J Antimicrob Agents 2000, 16(Suppl. 1):S3-S10.
12. Tupin A., Gualtieri M., Roquet-Baneres F., Morichaud Z., Brodolin K., Leonetti J.P. Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. Int J Antimicrob Agents 2010, 35:519-523.
13. Taylor D.N. Poorly absorbed antibiotics for the treatment of traveler's diarrhea. Clin Infect Dis 2005, 41(Suppl. 8):S564-S570.
14. Koo H.L., DuPont H.L. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010, 26:17-25.
15. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009, 58:403-410.
16. Johnson S., Schriever C., Galang M., Kelly C.P., Gerding D.N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007, 44:846-848.
17. Bass N.M. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl. 1):23-31.
18. Bass N.M., Mullen K.D., Sanyal A., Poordad F., Neff G., Leevy C.B., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
19. Huang D.B., DuPont H.L. Rifaximin-a novel antimicrobial for enteric infections. J Infect 2005, 50:97-106.
20. Marchese A., Salerno A., Pesce A., Debbia E.A., Schito G.C. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000, 46:253-266.
21. Hoover W.W., Gerlach E.H., Hoban D.J., Eliopoulos G.M., Pfaller M.A., Jones R.N. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993, 16:111-118.
22. Adachi J.A., DuPont H.L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006, 42:541-547.
23. Performance Standards for antimicrobial susceptibility testing; Eighteenth Informational Supplement. CLSI Document 2008, Clinical and Laboratory Standards Institute, M100-MS18.
24. Gustafsson I., Cars O., Andersson D.I. Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. J Antimicrob Chemother 2003, 52:258-263.
25. Hoiby N., Jarlov J.O., Kemp M., Tvede M., Bangsborg J.M., Kjerulf A., et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997, 349:167-169.
26. De Leo C., Eftimiadi C., Schito G.C. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986, 12:979-981.
27. Ruiz J., Mensa L., Pons M.J., Vila J., Gascon J. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 2008, 61:1016-1019.
28. Curry S.R., Marsh J.W., Shutt K.A., Muto C.A., O'Leary M.M., Saul M.I., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009, 48:425-429.
29. O'Connor J.R., Galang M.A., Sambol S.P., Hecht D.W., Vedantam G., Gerding D.N., et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008, 52:2813-2817.
30. Choong P.F., Dowsey M.M., Carr D., Daffy J., Stanley P. Risk factors associated with acute hip prosthetic joint infections and outcome of treatment with a rifampinbased regimen. Acta Orthop 2007, 78:755-765.
31. Murillo O., Domenech A., Euba G., Verdaguer R., Tubau F., Cabo J., et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect 2008, 57:229-235.
32. Baldoni D., Haschke M., Rajacic Z., Zimmerli W., Trampuz A. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother 2009, 53:1142-1148.
33. John A.K., Baldoni D., Haschke M., Rentsch K., Schaerli P., Zimmerli W., et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009, 53:2719-2724.
34. Hellmark B., Unemo M., Nilsdotter-Augustinsson A., Soderquist B. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect 2009, 15:238-244.
35. Robertson G.T., Bonventre E.J., Doyle T.B., Du Q., Duncan L., Morris T.W., et al. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. Antimicrob Agents Chemother 2008, 52:2324-2334.
36. Archer G.L., Climo M.W. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994, 38:2231-2237.
37. Archer G.L., Armstrong B.C. Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. J Infect Dis 1983, 147:642-649.
38. Kadurugamuwa J.L., Sin L.V., Yu J., Francis K.P., Kimura R., Purchio T., et al. Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. Antimicrob Agents Chemother 2003, 47:3130-3137.
39. Shen B., Remzi F.H., Lopez A.R., Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008, 8:26.
40. Corazza G.R., Di Stefano M., Scarpignato C. Treatment of functional bowel disorders: is there room for antibiotics?. Digestion 2006, 73(Suppl. 1):38-46.
41. DuPont H.L., Jiang Z.D., Okhuysen P.C., Ericsson C.D., de la Cabada F.J., Ke S., et al. Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. Clin Infect Dis 2005, 41(Suppl. 8):S571-S576.
42. Frieri G., Pimpo M.T., Scarpignato C. Management of colonic diverticular disease. Digestion 2006, 73(Suppl. 1):58-66.
43. Lanas A., Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?. Digestion 2006, 73(Suppl. 1):136-150.
44. MacDougall C., Powell J.P., Johnson C.K., Edmond M.B., Polk R.E. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005, 41:435-440.
45. Dellit T.H., Owens R.C., McGowan J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
46. Uckay I., Vernaz-Hegi N., Harbarth S., Stern R., Legout L., Vauthey L., et al. Activity and impact on antibiotic use and costs of a dedicated infectious diseases consultant on a septic orthopaedic unit. J Infect 2009, 58:205-212.